· Investment Strategies · 1 source
NYC VC Fund News: Eckuity Capital Holds First Close of Healthcare Growth Fund II
New York-based Eckuity Capital announced the first close of Fund II on June 26, 2026, extending its commercial-stage life sciences growth strategy across North America and Europe.
Editorial team
Eckuity Capital announced the first close of Fund II on June 26, 2026 — extending a healthcare growth equity strategy that is fully deployed across 14 companies in Fund I.
Key facts
- Firm: Eckuity Capital
- Date announced: June 26, 2026
- Fund: Eckuity Capital Fund II (first close)
- Focus: Commercial-stage life sciences — medtech, diagnostics, tech-enabled services
- Geography: North America and Western Europe
- HQ: New York, London, Miami
- Founder: Youssef Sebban (Managing Partner)
Fund II inaugural investment
Led Series C of Automata Technologies alongside Danaher — robotics and lab automation at commercial scale.
New partners added
- Paul Enever — Former McKinsey partner, 25 years in medtech; boards include GT Medical, Magnolia Medical; exit: Cardiva Medical to Haemonetics
- Alejandro Sanchez — Former McKinsey partner, co-founder Hermes Growth Partners; board: PreludeDx; exit: Biotheranostics to Hologic
Why this matters
Eckuity fills a niche between NYC seed life sciences VCs and mega buyout PE — commercial-stage healthcare growth with hands-on operating support. Fund I full deployment across 14 companies validates the model before Fund II scales.
- nyc-vc-news
- fund-close
- new-york-funds
- +2 more
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
